Kornimate/medical-research-clean huggingface dataset:
glucosamine/chondroitin and physical therapy effects on older population with knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: to see the effect of glucosamine chondratin sulfate with and without physiotherapy in knee osteoarthritis

it is a randomized control trail to evaluate the effectiveness of glucosamine chondratin sulfate alone and in combination with physiotherapy on knee osteoarthritis

Eligibility criteria:
inclusion criteria: * age \> 50 years with radiographic evidence of mild to moderate knee oa (kellgren lawrence grade ii \& iii 20) who met the acr clinical 21, * radiographic classification criteria or confirmation of mild to moderate radiographic evidence of knee oa from a personal physician * not currently participating in another intervention study exclusion criteria: * dementia (mini-mental state examination \[mmse\]\< 24) * active cancer other than skin cancer * anemia (participants with an hematocrit (hct)\< 32 (or a hemoglobin below10) were excluded due to possible inability to adequately exercise or the increased potential for increased risk for serious adverse cardiovascular events) * severe renal insufficiency (serum creat\> 2) * hepatic disease

Keywords: oa, chondratin sulfate, glucosamine, physiotherapy
obliterating diabetic microangiopathy of the diabetic foot

Conditions: Diabetic Foot

Summary: the purpose of this study will be the assessment of microangiopathy determined by the increase of capillary basement membrane thickness and decrease of capillary lumen area in the foot ulcer of 30 neuropathic and 30 neuroischemic type 2 diabetic patients

primary endpoint of the study is to quantitatively evaluate the presence of microangiopathy as increase of capillary basement membrane thickness and decrease of capillary lumen area determined by transmission electron microscopy analysis in type 2 diabetic patients with only motor-sensory neuropathy or chronic critical ischemia affected by foot ulcer. the following parameters will be evaluated: * presence of capillary (n/mm2) and thrombosis (%) and correlation of this quantitative histological data with ischemic parameters (tcpo2, ankle-brachial index) and risk of diastasis * correlation between presence of inflammatory infiltrate (leukocytes/mm2) with blood inflammatory parameters (erythrocyte sedimentation rate (esr), c-reactive protein, alpha-2 globulin) * rate of diastasis and/or time required for recovery associated with histopathological data * presence of acanthosis related to clinical and demographic variables

Eligibility criteria:
inclusion criteria:- * adult type 2 diabetic patients of either gender * diabetes for more than 10 years * motor-sensory diabetic neuropathy with or without chronic critical ischemia * local residents * ulcer with surgical therapy indication of removal the 1st ray because of gangrene or osteomyelitis exclusion criteria: * type 1 diabetic patients * diabetes for less than 10 years * renal replacement therapy * urgent surgical procedure for sepsis * immunosuppressive therapy * not local residents * cancer with adverse prognosis in months, or chemotheraputic treatment * ongoing or planned pregnancy * lack of consent to participate to the study

Keywords: diabetes foot ulcer
safety, tolerability, pharmacokinetics and protective efficacy of mam01 in healthy adults

Conditions: Malaria

Summary: this is a first-in-human (fih), randomized, two-part, dose-escalation trial of mam01 monoclonal antibody (mab) targeting the plasmodium falciparum (pf) circumsporozoite protein (csp). this study will evaluate the safety, tolerability, pharmacokinetics (pk), and protective efficacy of mam01, as well as safety and pk of repeat subcutaneous (sc) dosing. part a will have a double-blind, placebo-controlled design. part b will randomize participants to one of three open-label mam01 dose groups; a separate non-randomized group will be enrolled to include participants who will receive no treatment and act as infectivity controls.


Eligibility criteria:
inclusion criteria: * participants who are healthy as determined by medical evaluation including medical history, physical examination and laboratory tests * body mass index (bmi) 18 to 30 kilograms per square meter (kg/m\^2) (inclusive) to a maximum of 220 pounds * both males and females are eligible to participate as per the following: a. female participants physically capable of pregnancy, have at least one negative pregnancy test during screening, on the day of enrollment, prior to investigational product (ip) administration, prior to chm and at the start of antimalarial treatment, and who agree to use effective contraception to avoid pregnancy from 28 days before enrollment through 10 months after last administration of investigational product are eligible to participate. * capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and the trial protocol, and completion of a test of understanding if he/she may participate in the chmi procedure * reported completion of primary coronavirus disease (covid) vaccine series is documented exclusion criteria: * acute illness or fever ≥99.5°fahrenheit (f) (or ≥37.5 degrees celsius) on day of dosing * women who are pregnant or breastfeeding * evidence and/or history of clinically significant medical condition(s) as judged by the investigator, including malignancies, diabetes mellitus, and unstable or uncontrolled hypertension * a 5-year cardiovascular risk of ≥10% using the gaziano nomogram * history of any autoimmune disease or immune deficiency or other impairment to the immune system, including but not limited to human immunodeficiency virus (hiv), autoimmune conditions or immunosuppressive therapy * participation in an interventional clinical trial and/or receipt of any investigational drug within 180 days prior to administration of trial drug on day 0 * anticipated use of medications known to cause drug reactions with chloroquine or atovaquone-proguanil (malarone) such as cimetidine, metoclopramide, antacids, and kaolin note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: healthy volunteers mam01 monoclonal antibody first-in-human dose-escalation single ascending dose multiple ascending dose recruiting malaria vaccine mosquito gates prevention phase 1 nonprofit
comparison of the effects of different massage techniques in women with primary dysmenorrhea

Conditions: Primary Dysmenorrhea

Summary: the aim of this study was to compare the effects of different massage techniques on pain, primary dysmenorrhea (pd)-related symptoms and functional and emotional influence in women with pd.

primary dysmenorrhea is defined as painful menstrual cramps without an underlying pelvic pathology or organic problem. massage, which is one of the physiotherapy methods that reduces pain by acting on the autonomic nervous system and circulation, has an important place in the management of pd among non-pharmacological treatment approaches. in the literature, there are studies on the use of classical massage and connective tissue massage in women with pd for reducing menstrual pain and pd-related symptoms. however, to the best of our knowledge, no study has been found comparing classical massage and connective tissue massage in pd management.

Eligibility criteria:
inclusion criteria: * over 18 years of age * women with a complaint of primary dysmenorrhea, * volunteer women who have a regular menstrual cycle (28 ± 7 days) * women who have menstrual pain intensity greater than 40 mm according to the visual analogue scale considering the last 6 months exclusion criteria: * having gastrointestinal, urogynecological, autoimmune, psychiatric diseases and/or other chronic pain syndromes, * those who have given birth, * those who have a pregnancy status, * those who use intrauterine devices, * those who have had pelvic surgery, * those who use chronic medications, including oral contraceptives or antidepressants, for at least 6 months before the study, * those with a pathological history and radiological findings showing secondary dysmenorrhea
intervention and mechanisms of alanyl-glutamine for inflammation, nutrition, and enteropathy

Conditions: Malnutrition; Environmental Enteropathy; Diarrhea

Summary: several host factors underlie the pathogenesis of the reciprocal cycle of childhood diarrhea and undernutrition in developing countries. these include intestinal inflammation, mucosal damage, and alterations in intestinal barrier function that lead to malabsorption, growth failure, and heightened susceptibility to recurrent and prolonged episodes of diarrhea. recent studies from northeast brazil demonstrate the benefits of a novel alanyl-glutamine-based oral rehydration and nutrition therapy (ala-gln ornt) in speeding the recovery of damaged intestinal barrier function in cell culture, animal models, patients with aids, and underweight children. oral supplementation with alanyl-glutamine (ala-gln; 24g a day for 10 days) improves short-term gut integrity and weight velocity 4 months after therapy in a group of undernourished children from northeast brazil. intervention and mechanisms of alanyl-glutamine for inflammation, nutrition, and enteropathy (imagine) is a study designed to answer the following questions: 1) what is the lowest dose of ala-gln that improves intestinal barrier function, intestinal inflammation, and nutritional status in children at risk of underweight, wasting, or stunting? 2) what are the mechanisms by which ala-gln exerts these benefits?


Eligibility criteria:
inclusion criteria: 1. children who are undernourished or at risk of undernutrition, with anthropometric z-scores less than or equal to -1 for one of these parameters: height-for-age, weight-for-age, or weight-for-height. 2. children ages 2 months to 5 years old. exclusion criteria: 1. children who are exclusively breastfed. 2. have participated in another intervention study in the past two years. 3. fever greater than 38.8 ° c. 4. use of antibiotics. 5. systemic disease or other serious medical condition (including, but not limited to meningitis, pneumonia, tuberculosis, and chickenpox). 6. children who are unable to ingest, retain or absorb nutritional supplements. 7. children whose families plan to move from the study area within the next 6 months.

Keywords: l-alanyl-l-glutamine environmental enteric dysfunction tropical enteropathy
kinematic biofeedback on gait quality in stroke

Conditions: Stroke

Summary: walking disorder is the most common and concerning issue for individuals with stroke. previous studies have often used improvements in walking speed and distance as reference indicators for the advancement of gait performance in individuals with stroke. however, for individuals with chronic stroke, considering gait symmetry and variability to enhance gait quality as the primary intervention target may be more crucial. according to a literature review, it can be inferred that the application of biofeedback to detect gait quality may be an effective approach to improve gait symmetry and variability in individuals with stroke. however, there is still insufficient research evidence on this issue. therefore, this study aims to investigate the effects of a kinematic biofeedback device system, which detects hip joint angles, on gait quality in individuals with chronic stroke.


Eligibility criteria:
inclusion criteria: * first stroke * stroke onset time ≥ 6 months * functional ambulation category ≥3 * passive range of motion of affected hip extension is at least 10 degrees * mini-mental state measurement score ≥ 24 points exclusion criteria: * modified ashworth scale of affected ankle plantar flexors ≥ 2 * muscle strength of affected ankle plantar flexors via manual muscle testing ≤ 1 * uncorrected auditory impairment * severe cardiovascular disease or uncontrolled hypertension * other orthopedic diseases that may affect walking ability * other neurological disease except stroke

Keywords: biofeedback gait symmetry gait variability
axis 2: ax200 for the treatment of ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: the purpose of this study is to assess the efficacy of ax200 (filgrastim) in the treatment of acute ischemic stroke and to assess the safety and tolerability of ax200.


Eligibility criteria:
major inclusion criteria: * diagnosis of acute ischemic stroke with an onset within 9 hours prior to start of study agent administration * ischemic stroke in the mca territory confirmed by mri (diffusion) * age ≥18 years and ≤85 years * lesion size on dwi ≥15 ccm * written informed consent major exclusion criteria: * prior to current stroke: inability to walk or to lead an independent life * life expectancy less or equal 6 months * stupor or coma * lacunar infarct * any evidence of ich * malignant hypertension * presence of history of active malignancies * platelet count \<100/nl at randomization * leukocyte count \>20/nl at randomization * congenital neutropenia * pregnant or lactating women
depressive symptoms among medical students

Conditions: Depressive Symptoms

Summary: depression is a common mental disorder, people with depression feel sadness anxious, loss of interest or pleasure, hopeless, helpless, worthless feelings of guilt and poor concentration. it can impair person's ability to function at work or school, or cope with daily life. it can lead to suicide.

depressive symptoms are higher among women and its prevalence among university students was reported to be higher than the general population .there are various risk factors of depressive symptoms among university students, lower socioeconomic status, poor academic performance, overweight, life stressors, family history of psychiatric disorders, sleeping problems, and exposure to patients' suffering. several studies were conducted among medical students in different egyptian universities to detect prevalence of depressive symptoms which were 42.9% in al-azhar uni-versity, cairo, 60.8% in fayoum university, 59.2% in mansoura university and 57.9% in alexandria university. a sense of control means having a feeling of autonomy, of choosing how you spend your time, of doing your own work in your own way, which is a key component of happiness. depressive symptoms more common in those who feel there is little they can do to change important things in their lives. medical education is considered stressful. medical students have psychological and academic stressors during their revolution from insecure students to young knowledgeable physicians, which were determined to be associated with depressive symptoms and decrease the quality of life and academic achievements.

Eligibility criteria:
inclusion criteria: all egyptian medical students at faculty of medicine, assiut university in the academic year 2018-2019 exclusion criteria: non-egyptian medical students
whey protein, resistance training, and changes in body composition

Conditions: Obesity

Summary: the objective of this project is to determine the effect of 9 months of progressive resistance training with daily whey protein supplements on the body composition (changes in muscle and fat) in young adults. the investigators hypothesize that those individuals who receive whey protein supplements will have larger gains in muscle and larger losses of fat tissue in response to resistance training compared to those who receive supplements of soy or carbohydrate.

healthy men and women will be recruited to participate in 9 months of supervised resistance training (3 days/wk) and will be randomized to one of three daily supplement groups: whey protein, soy protein, or carbohydrate control. body weight, muscular strength and endurance, and resting blood pressure will be assessed at baseline, 3, 6 and 9 months. body composition will be assessed at baseline, 3, 5, 7, and 9 months. a sub-sample (n = 17 per group, assessed at baseline and 9 months) will be randomly selected for muscle samples of the upper leg to determine changes in the size of muscle fibers, and chemical factors associated with muscle growth. blood samples will be obtained from sub-sample participants to assess changes in glucose and fat metabolism, as well as other chemicals likely to promote or inhibit muscle growth. we will also assess changes in daily energy expenditure and the use of fuel to produce energy (carbohydrate, fat, protein) that may result from the intervention. we hypothesize that those individuals who receive whey protein supplements will have larger gains in muscle and larger losses of fat tissue in response to resistance training compared to those who receive supplements of soy or carbohydrate.

Eligibility criteria:
inclusion criteria: * bmi 25-39.9 * must be 18- 30 years old * sedentary * no medications * stable weight for at least 3 months exclusion criteria: * tobacco/drug user * metabolism altering medication * gain/lost 10lbs in the last 3 months * current exerciser

Keywords: whey protein soy protein resistance training weight management
treatment with intensity modulated radiotherapy on the change of cognitive function in nasopharyngeal carcinoma patients: a prospective cohort study

Conditions: Nasopharyngeal Carcinoma (NPC); Cognitive Function

Summary: this is an observational cohort study aimed at investigating changes in hippocampal function and its impact on cognitive function in newly diagnosed nasopharyngeal carcinoma patients without metastasis, from baseline to a period after radiotherapy.


Eligibility criteria:
inclusion criteria: * newly diagnosed nasopharyngeal carcinoma patients confirmed by pathology, who have not received surgical, induction chemotherapy, radiotherapy, or other anti-tumor treatments; * clinical stage classified as ajcc 8th edition stage i-iva, with no distant metastasis, and who are scheduled to undergo intensity-modulated radiotherapy (imrt) according to clinical plans; * pathologically diagnosed as non-keratinizing nasopharyngeal carcinoma (differentiated or undifferentiated type, i.e., who type ii or iii); * all participants are han chinese and right-handed; * age between 18 and 60 years, with an education level of junior high school or above; * no history of neurological diseases or head trauma; * no other severe systemic diseases other than nasopharyngeal carcinoma; * no hippocampal invasion before treatment; * routine mri before treatment shows no abnormal lesions in the hippocampus; * no family history of mental illness. exclusion criteria: * routine mri before treatment shows abnormal lesions in the hippocampus; * contraindications for magnetic resonance examination; * concurrent other brain diseases; * pathologically diagnosed as keratinizing squamous cell carcinoma (who type i); * patients with recurrence or distant metastasis; * patients who have previously undergone radiotherapy or chemotherapy; * abnormal function of vital organs such as heart, brain, or lungs; * history of head trauma or mental/neuro diseases; * age less than 18 years or greater than 60 years; * patients whose initial treatment plan is changed during the observation * period due to disease progression (including residual tumors after * radiotherapy, tumor recurrence, or newly developed distant metastasis); * patients with diabetes or hypertension; * those unable to cooperate in completing neurocognitive scale testing; * those with other uncontrolled severe diseases.
screening in primary care of advanced liver fibrosis in nafld and/or alcoholic patients (improve study)

Conditions: NAFLD; Alcohol-Related Disorder; Liver Fibrosis

Summary: the main objective is to determine the performance of the simple elift blood test for advanced liver fibrosis screening in nafld and/or alcoholic patients in primary care.

elift, is a new blood fibrosis test specifically dedicated for general practitioners with simple parameters and easy "by head" calculation. using the recommended cut-offs (elift ≥8), elift sensitivity was 86%. this result position elift an as interesting tool for the screening of advanced liver fibrosis in large populations. as our preliminary results come from very selected patients, i.e. patients from tertiary centres who underwent a liver biopsy, we now need to evaluate in the real condition of primary care setting whether the use of elift will help general practitioners to screen advanced liver fibrosis in their asymptomatic nafld and alcoholic patients.

Eligibility criteria:
inclusion criteria: * nafld and/or alcoholic patient defined by ≥1 of the following criteria: * excessive alcohol consumption: \>210 g/week (men), \>140 g/week (women) * type 2 diabetes * ≥2 metabolic factors among: 1/bmi ≥25kg/m2; 2/elevated blood pressure (antihypertensive drug, or systolic blood pressure ≥130mmhg, or diastolic blood pressure ≥85mmhg), 3/dyslipidemia (lipid-lowering drug, or hdl cholesterol \ 300 ng/ml (men)/\>200 ng/ml (women)) * bright liver at ultrasonography without steatosis-inducing drug * obtaining the signature of the consent to participate in the study exclusion criteria: * already ongoing specialized follow-up for a chronic liver disease * altered health status with poor short-term prognosis, not compatible with a screening procedure * decompensated cirrhosis (hepatic encephalopathy, jaundice, ascites, variceal bleeding, hepatorenal syndrome) * acute infection * inadequate understanding of the french language * pregnant, breastfeeding or parturient women * persons deprived of their liberty by judicial or administrative decision * persons subject to legal protection measures * persons unable to consent * refusal to participate
a study to evaluate impact of ibrutinib on the quality of life (qol) in patients with chronic lymphocytic leukemia

Conditions: CLL

Summary: the aim of this study is to evaluate the impact of ibrutinib monotherapy in the qol of subjects with chronic lymphocytic leukemia (cll) based in european quality of life 5 dimensions (eq-5d) and facit- fatigue questionnaires assessment from baseline to 1 year of treatment in argentinian routine clinical practice.


Eligibility criteria:
inclusion criteria: * written informed consent obtained prior to any screening procedure * patients 18 years or older, to be treated with ibrutinib, able to answer the complete qol questionnaires. * diagnosis of cll, according to international workshop on chronic lymphocytic leukemia (iwcll) criteria, with pathology confirmation (world health organization 2008). * patients with cll in first-line or with prior therapies or treatment-naïve patients that harbours deletion 17p according to fluorescence in situ hybridization (fish) standards with an indication of treatment with ibrutinib. exclusion criteria: * pregnant and breast-feeding patients * impairment of ingestion and/or absorption of ibrutinib * mental or physical limitation to complete the qol questionnaires.